Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients.

ARDS COVID-19 Prognostication TREM-1

Journal

Intensive care medicine experimental
ISSN: 2197-425X
Titre abrégé: Intensive Care Med Exp
Pays: Germany
ID NLM: 101645149

Informations de publication

Date de publication:
14 Aug 2023
Historique:
received: 21 04 2023
accepted: 05 07 2023
medline: 14 8 2023
pubmed: 14 8 2023
entrez: 13 8 2023
Statut: epublish

Résumé

The immuno-receptor Triggering Expressed on Myeloid cells-1 (TREM-1) is activated during bacterial infectious diseases, where it amplifies the inflammatory response. Small studies suggest that TREM-1 could be involved in viral infections, including COVID-19. We here aim to decipher whether plasma concentration of the soluble form of TREM-1 (sTREM-1) could predict the outcome of hospitalized COVID-19 patients. We conducted a multicentre prospective observational study in 3 university hospitals in France. Consecutive hospitalized patients with confirmed infection with SARS-CoV-2 were enrolled. Plasma concentration of sTREM-1 was measured on admission and then at days 4, 6, 8, 14, 21, and 28 in patients admitted into an ICU (ICU cohort: ICUC) or 3 times a week for patients hospitalized in a medical ward (Conventional Cohort: ConvC). Clinical and biological data were prospectively recorded and patients were followed-up for 90 days. For medical ward patients, the outcome was deemed complicated in case of requirement of increased oxygen supply > 5 L/min, transfer to an ICU, or death. For Intensive Care Unit (ICU) patients, complicated outcome was defined by death in the ICU. Plasma concentration of sTREM-1 at inclusion was higher in ICU patients (n = 269) than in medical ward patients (n = 562) (224 pg/mL (IQR 144-320) vs 147 pg/mL (76-249), p < 0.0001), and higher in patients with a complicated outcome in both cohorts: 178 (94-300) vs 135 pg/mL (70-220), p < 0.0001 in the ward patients, and 342 (288-532) vs 206 pg/mL (134-291), p < 0.0001 in the ICU patients. Elevated sTREM-1 baseline concentration was an independent predictor of complicated outcomes (Hazard Ratio (HR) = 1.5 (1.1-2.1), p = 0.02 in ward patients; HR = 3.8 (1.8-8.0), p = 0.0003 in ICU patients). An sTREM-1 plasma concentration of 224 pg/mL had a sensitivity of 42%, and a specificity of 76% in the ConvC for complicated outcome. In the ICUC, a 287 pg/mL cutoff had a sensitivity of 78%, and a specificity of 74% for death. The sTREM-1 concentrations increased over time in the ConvC patients with a complicated outcome (p = 0.017), but not in the ICUC patients. In COVID-19 patients, plasma concentration of sTREM-1 is an independent predictor of the outcome, although its positive and negative likelihood ratio are not good enough to guide clinical decision as a standalone marker.

Sections du résumé

BACKGROUND BACKGROUND
The immuno-receptor Triggering Expressed on Myeloid cells-1 (TREM-1) is activated during bacterial infectious diseases, where it amplifies the inflammatory response. Small studies suggest that TREM-1 could be involved in viral infections, including COVID-19. We here aim to decipher whether plasma concentration of the soluble form of TREM-1 (sTREM-1) could predict the outcome of hospitalized COVID-19 patients.
METHODS METHODS
We conducted a multicentre prospective observational study in 3 university hospitals in France. Consecutive hospitalized patients with confirmed infection with SARS-CoV-2 were enrolled. Plasma concentration of sTREM-1 was measured on admission and then at days 4, 6, 8, 14, 21, and 28 in patients admitted into an ICU (ICU cohort: ICUC) or 3 times a week for patients hospitalized in a medical ward (Conventional Cohort: ConvC). Clinical and biological data were prospectively recorded and patients were followed-up for 90 days. For medical ward patients, the outcome was deemed complicated in case of requirement of increased oxygen supply > 5 L/min, transfer to an ICU, or death. For Intensive Care Unit (ICU) patients, complicated outcome was defined by death in the ICU.
RESULTS RESULTS
Plasma concentration of sTREM-1 at inclusion was higher in ICU patients (n = 269) than in medical ward patients (n = 562) (224 pg/mL (IQR 144-320) vs 147 pg/mL (76-249), p < 0.0001), and higher in patients with a complicated outcome in both cohorts: 178 (94-300) vs 135 pg/mL (70-220), p < 0.0001 in the ward patients, and 342 (288-532) vs 206 pg/mL (134-291), p < 0.0001 in the ICU patients. Elevated sTREM-1 baseline concentration was an independent predictor of complicated outcomes (Hazard Ratio (HR) = 1.5 (1.1-2.1), p = 0.02 in ward patients; HR = 3.8 (1.8-8.0), p = 0.0003 in ICU patients). An sTREM-1 plasma concentration of 224 pg/mL had a sensitivity of 42%, and a specificity of 76% in the ConvC for complicated outcome. In the ICUC, a 287 pg/mL cutoff had a sensitivity of 78%, and a specificity of 74% for death. The sTREM-1 concentrations increased over time in the ConvC patients with a complicated outcome (p = 0.017), but not in the ICUC patients.
CONCLUSIONS CONCLUSIONS
In COVID-19 patients, plasma concentration of sTREM-1 is an independent predictor of the outcome, although its positive and negative likelihood ratio are not good enough to guide clinical decision as a standalone marker.

Identifiants

pubmed: 37574520
doi: 10.1186/s40635-023-00532-4
pii: 10.1186/s40635-023-00532-4
pmc: PMC10423708
doi:

Types de publication

Journal Article

Langues

eng

Pagination

51

Informations de copyright

© 2023. The Author(s).

Références

Biomark Insights. 2022 Jun 16;17:11772719221106600
pubmed: 35747885
Biosci Rep. 2021 Jul 30;41(7):
pubmed: 34195785
J Immunol. 2007 Sep 15;179(6):4065-73
pubmed: 17785845
PLoS Pathog. 2019 Jul 1;15(7):e1007883
pubmed: 31260499
PLoS Pathog. 2013 Feb;9(2):e1003168
pubmed: 23544010
J Virol. 2006 Jul;80(14):7235-44
pubmed: 16809329
Cell Mol Immunol. 2021 Aug;18(8):2054-2056
pubmed: 34282296
Clin Immunol. 2021 Feb;223:108650
pubmed: 33316373
J Leukoc Biol. 2013 Feb;93(2):209-15
pubmed: 23108097
Br J Clin Pharmacol. 2018 Oct;84(10):2270-2279
pubmed: 29885068
Biomarkers. 2017 Feb;22(1):63-69
pubmed: 27319606
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Intensive Care Med. 2020 Jul;46(7):1425-1437
pubmed: 32468087
Front Cell Infect Microbiol. 2022 Dec 13;12:1038908
pubmed: 36583110
JAMA. 2020 Sep 3;:
pubmed: 32880615
J Allergy Clin Immunol. 2021 Jan;147(1):99-106.e4
pubmed: 33045281
Crit Care Clin. 2020 Jan;36(1):41-54
pubmed: 31733681
Front Immunol. 2021 Jun 07;12:696085
pubmed: 34163491
Immunol Lett. 2014 Mar-Apr;158(1-2):183-8
pubmed: 24447863
PLoS One. 2013;8(1):e55199
pubmed: 23383108
Intensive Care Med. 2005 Apr;31(4):594-7
pubmed: 15754199
J Thorac Dis. 2022 May;14(5):1478-1487
pubmed: 35693606
Curr Opin Immunol. 2009 Feb;21(1):38-46
pubmed: 19230638
Front Immunol. 2021 May 05;12:666223
pubmed: 34046036
Viruses. 2021 Dec 15;13(12):
pubmed: 34960790
Sci Rep. 2020 Mar 2;10(1):3810
pubmed: 32123257
J Appl Lab Med. 2020 Sep 1;5(5):1038-1049
pubmed: 32573713
Cell Mol Immunol. 2019 May;16(5):460-472
pubmed: 29568119

Auteurs

Sébastien Gibot (S)

Médecine Intensive et Réanimation, Hôpital Central, Université de Lorraine, CHRU-Nancy, 54000, Nancy, France. S.gibot@chru-nancy.fr.
Service de Médecine Intensive et Réanimation, Hôpital Central, 29 Avenue de Lattre de Tassigny, 54035, Nancy Cedex, France. S.gibot@chru-nancy.fr.

Thomas Lafon (T)

Emergency Department, Limoges University Hospital Center, 87000, Limoges, France.
Inserm CIC 1435, Limoges University Hospital Center, 87000, Limoges, France.

Laurent Jacquin (L)

Emergency Department, Hospices Civils de Lyon, Hôpital Edouard Herriot, 69003, Lyon, France.

Benjamin Lefevre (B)

Service des Maladies Infectieuses et Tropicales, Université de Lorraine, CHRU-Nancy, 54000, Nancy, France.

Antoine Kimmoun (A)

Médecine Intensive et Réanimation, Hôpital Brabois, Université de Lorraine, CHRU-Nancy, 54500, Vandoeuvre-Les-Nancy, France.

Anne Guillaumot (A)

Département de Pneumologie, Hôpital Brabois, Université de Lorraine, CHRU-Nancy, 54500, Vandoeuvre-Les-Nancy, France.

Marie-Reine Losser (MR)

Réanimation Chirurgicale, Hôpital Brabois, Université de Lorraine, CHRU-Nancy, 54500, Vandoeuvre-Les-Nancy, France.

Marion Douplat (M)

Emergency Department, Hospices Civils de Lyon, Hôpital Lyon Sud Pierre Benite, 69000, Lyon, France.

Laurent Argaud (L)

Service de Médecine Intensive-Réanimation, Hospices Civils de Lyon, Hôpital Edouard Herriot, 69003, Lyon, France.

Guillaume De Ciancio (G)

Département de Cardiologie, Hôpital Brabois, Université de Lorraine, CHRU-Nancy, 54500, Vandoeuvre-Les-Nancy, France.

Lucie Jolly (L)

Inotrem Sa, Faculté de Médecine de Nancy, 54500, Vandoeuvre-Les-Nancy, France.

Nina Touly (N)

Inotrem Sa, Faculté de Médecine de Nancy, 54500, Vandoeuvre-Les-Nancy, France.

Marc Derive (M)

Inotrem Sa, Faculté de Médecine de Nancy, 54500, Vandoeuvre-Les-Nancy, France.

Catherine Malaplate (C)

Laboratoire de Biochimie, Hôpital Brabois, Université de Lorraine, CHRU-Nancy, 54500, Vandoeuvre-Les-Nancy, France.
Centre de Ressources Biologiques Lorraine, CHRU Nancy, Hôpital Brabois, 54500, Vandoeuvre-Les-Nancy, France.

Amandine Luc (A)

Unité de Méthodologie, Data Management et Statistiques, Hôpital Brabois, Université de Lorraine, CHRU-Nancy, 54500, Vandoeuvre-Les-Nancy, France.

Cédric Baumann (C)

Unité de Méthodologie, Data Management et Statistiques, Hôpital Brabois, Université de Lorraine, CHRU-Nancy, 54500, Vandoeuvre-Les-Nancy, France.

Bruno François (B)

Réanimation Polyvalente et Inserm CIC-1435 & UMR-1092, CHU Limoges, 87000, Limoges, France.

Classifications MeSH